
|Articles|June 9, 2008
Allergan buys Aczone Gel 5 percent from QLT USA
Irvine, Calif. - Allergan has announced it has entered an agreement with QLT USA to purchase Aczone (dapsone) Gel 5 percent, according to socalTech.com.
Advertisement
Irvine, Calif.
- Allergan has announced it has entered an agreement with QLT USA to purchase Aczone (dapsone) Gel 5 percent, according to socalTech.com.
Allergan will pay about $150 million for all assets related to Aczone, a topical treatment for acne vulgaris, which could reach revenues in excess of $75 million per year.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
CSU With Biochemical C1 Inhibitor Deficiency: Case Report Raises Diagnostic Questions
2
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
3
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
4
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
5











